Study guide
Direct Oral Anticoagulant (DOAC) Reversal
ABPN Neurocritical Care Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU
Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU
2 Chapter 2: Cerebral Physiology & Intracranial Dynamics
Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes
3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management
Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions
4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management
Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy
5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management
Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury
6 Chapter 6: Neuropharmacology, Analgesia & Sedation
ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU
7 Bleeding, Thrombosis & Hematologic Emergencies
Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity
8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine
Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention
9 Systemic Trauma & Environmental Injury
Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging
10 Cardiac Emergencies & Mechanical Support
IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies
11 Kidney Injury, Acid–Base & Renal Replacement
Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement
12 Systemic Infection & Endocrine Emergencies
Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies
13 Gastrointestinal & Hepatic Emergencies
Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects
14 Chapter 9: Neuroimaging in the Neuro-ICU
Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness
15 Chapter 10: Electrophysiology & Neuromonitoring
Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler
16 Angiography, Electrodiagnosis & CSF Analysis
Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage
17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria
Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria
18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies
Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction
19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage
Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH
20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia
Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations
21 Venous, Spinal & Traumatic Vascular Disease
Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury
22 Chapter 15: Traumatic Brain & Spinal Cord Injury
Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes
23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies
Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure
24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis
Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies
25 Neuroinflammation & Neurooncology
Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies
26 Pregnancy, Transplantation & Pediatric Care
Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care
27 Chapter 18: Neurosurgical & Perioperative Emergencies
Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies
28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU
Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor
Direct Oral Anticoagulant (DOAC) Reversal
Key Takeaways Explain This Topic AI
Idarucizumab specifically reverses dabigatran, commonly 5 g IV as two sequential 2.5-g doses.
US andexanet sales ended in December 2025 after FDA safety concerns; current local availability and guidance matter.
PCC-based factor-Xa-inhibitor bleeding strategies are nonspecific, carry thrombotic risk, and do not remove the drug.
Normal PT/INR, aPTT, or routine viscoelastic tests do not reliably exclude clinically significant DOAC activity.
Reassess hemostasis, kidney function, thrombosis risk, and the subsequent anticoagulation plan after emergency treatment.
Last updated: October 2026
- Direct Oral Anticoagulants and Intracranial Bleeding
- Establish Whether Clinically Important Exposure Is Present
Record the exact anticoagulant, indication, dose, last administration, adherence, kidney and liver function, interacting medication, and possible overdose. Obtain emergency imaging, stabilize airway and circulation, and involve the appropriate stroke, trauma, neurosurgical, hematology, and pharmacy teams. Stop the drug and treat life-threatening bleeding promptly. Exposure assessment and hemostatic treatment should proceed in parallel when the history strongly supports a clinically relevant effect; a slow laboratory result must not become an avoidable delay.
Dabigatran inhibits thrombin, whereas apixaban, rivaroxaban, and edoxaban inhibit factor Xa. These targets determine which specific antibody or decoy approaches can work. Vitamin K does not reverse a DOAC, and protamine does not neutralize these drugs. Platelet transfusion is not a DOAC antidote. Associated thrombocytopenia, trauma-induced coagulopathy, fibrinolysis, or another anticoagulant can require additional targeted management rather than assuming one product corrects the whole problem.
Elapsed time alone is not an exact measure of drug activity. Kidney impairment is especially important for dabigatran, and accumulation or interacting drugs can prolong exposure. A normal creatinine in a frail person may not mean normal clearance. Conversely, an old prescription does not prove a recent dose was taken. Integrate reliable medication records and the severity and trajectory of the hemorrhage.
Dabigatran and Idarucizumab
Idarucizumab is a humanized antibody fragment that binds dabigatran and its active glucuronide metabolites with high affinity. The standard adult dose is 5 g IV, supplied as two 2.5-g doses administered sequentially according to the product instructions. It can rapidly reverse measured anticoagulant activity, but a laboratory reversal endpoint is not a guarantee that every bleeding site immediately stops or that neurologic outcome will improve.
Obtain and follow appropriate coagulation testing when available, imaging, examination, and clinical hemostasis. Recurrent or persistent dabigatran activity can occur, particularly with a large drug burden or impaired elimination. An additional 5-g dose can be considered under the label in specified recurrent-bleeding or urgent-procedure circumstances with elevated relevant clotting tests; evidence for repeat treatment is limited. Do not repeat doses merely because one nonspecific test remains abnormal without interpreting the entire situation.
The antibody fragment does not itself replace clotting factors, but reversal does not create zero thrombotic risk. Patients have an underlying reason for anticoagulation, and critical illness and treatment interruption can produce thromboembolic events. Plan subsequent prophylaxis and eventual anticoagulation reassessment when bleeding is controlled. The timing and indication require a separate risk decision.
Hemodialysis can remove dabigatran because protein binding is relatively low. It is an option in selected persistent-exposure, overdose, severe renal-failure, or antidote-unavailable situations, with attention to rebound and access-related bleeding. It is not an equally rapid substitute for immediately available specific reversal in every intracranial emergency. Recent ingestion may justify activated charcoal after toxicology assessment and airway protection; a rigid two-hour boundary does not replace consideration of the drug, timing, and aspiration risk.
Factor Xa Inhibitors and Current US Practice
Andexanet was developed as a modified factor-Xa decoy and historically used for selected apixaban- or rivaroxaban-associated life-threatening bleeding. Current availability must be checked separately from older guideline recommendations. The FDA's December 2025 safety communication described serious thromboembolic concerns, and AstraZeneca ended US commercial sales on December 22, 2025 while seeking voluntary withdrawal. A US study guide reviewed in October 2026 should not present it as routinely marketed treatment.
Do not mix adverse-event percentages from different ANNEXA reports or infer a positive functional result from improved hemostatic efficacy alone. ANNEXA-I and the later regulatory assessment involve specific endpoints and analysis sets. The practical lesson is to read the current regulator communication and actual trial outcomes rather than presenting an undifferentiated three-fold-risk slogan as the complete evidence.
PCC-based strategies are commonly used under current institutional guidance for major factor-Xa-inhibitor bleeding. 4F-PCC supplies factors II, VII, IX, and X and supports thrombin generation. It does not bind or remove the inhibitor, and its action should not be described as a direct chemical antidote or a guaranteed competition that normalizes anti-Xa activity. Weight-based regimens, often 25–50 units/kg, and validated fixed-dose protocols are used; selection, maximum dose, and repeat use depend on the protocol and clinical assessment.
Activated PCC is another nonspecific strategy in selected settings. Neither PCC type is free of thrombosis risk, and no single dose or agent is universally mandated across all facilities. Involve specialists when the exposure, severity, or available products make the choice uncertain. Factor-Xa inhibitors are highly protein bound, so conventional dialysis is generally ineffective for meaningful removal. Fresh frozen plasma does not supply a specific factor-Xa-inhibitor antidote.
Interpret the Laboratory Tests Correctly
Test Useful interpretation Important limit
PT/INR and aPTT Assess other coagulation abnormalities and some drug-related changes Normal results do not reliably exclude important DOAC activity
Thrombin time Very sensitive to dabigatran with an appropriate assay A prolonged result is not a quantitative drug concentration
Dilute thrombin time or ecarin-based assay Can assess dabigatran activity using the appropriate method Availability, calibration, and interpretation matter
Drug-calibrated anti-Xa Can quantify a specific factor-Xa inhibitor Heparin calibration is not automatically interchangeable
Routine TEG or ROTEM Can inform broader clot assessment Normal tracings do not establish absence of DOAC effect or complete reversal
A drug concentration threshold used for one procedure or protocol should not be applied universally to every bleeding emergency. After PCC, anti-Xa activity can remain elevated even when hemostasis improves. Conversely, a reassuring routine tracing cannot prove that the patient is safe for an invasive procedure. Repeat clinical and imaging assessment and interpret testing with pharmacy and the laboratory.
Sources: FDA andexanet safety communication and idarucizumab prescribing information .